Six Month Data Reported for WAVE I Study of Renal Denervation Therapy for Hypertension at EuroPCR Meeting in ParisMay 23, 2013
Kona Surround Sound® Technology Utilizes Externally-Delivered Ultrasound to Treat Drug-Resistant Hypertension
Dr. Apelian will be responsible for the clinical development of Achillion's portfolio of compounds to treat HCV. In addition, Achillion added Kevin Kucharski, formerly head of clinical operations at Pharmasset, as Senior VP of Clinical Operations.
Celator® Pharmaceuticals Raises $32.5 Million Completing A $39.3 Million Private Placement FinancingApril 30, 2013
Celator raised $39.3 million to support the late-stage clinical development of the Company's lead investigational product, CPX-351 (cytarabine:daunorubicin) Liposome Injection, which is being studied in a Phase 3 clinical study.